These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9667644)

  • 21. Segmentation of dynamic contrast enhanced magnetic resonance imaging data.
    Nielsen T; Mouridsen K; Maxwell RJ; Stødkilde-Jørgensen H; Østergaard L; Horsman MR
    Acta Oncol; 2008; 47(7):1265-70. PubMed ID: 18661437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.
    Kirwan IG; Loadman PM; Swaine DJ; Anthoney DA; Pettit GR; Lippert JW; Shnyder SD; Cooper PA; Bibby MC
    Clin Cancer Res; 2004 Feb; 10(4):1446-53. PubMed ID: 14977848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An assessment of artefacts in localized and non-localized 31P MRS studies of phosphate metabolites and pH in rat tumours.
    Howe FA; Stubbs M; Rodrigues LM; Griffiths JR
    NMR Biomed; 1993; 6(1):43-52. PubMed ID: 8457426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimations of intra- and extracellular volume and pH by 31P magnetic resonance spectroscopy: effect of therapy on RIF-1 tumours.
    Bhujwalla ZM; McCoy CL; Glickson JD; Gillies RJ; Stubbs M
    Br J Cancer; 1998 Sep; 78(5):606-11. PubMed ID: 9744499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
    Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
    World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of blood flow modification on intra- and extracellular pH measured by 31P magnetic resonance spectroscopy in murine tumours.
    McCoy CL; Parkins CS; Chaplin DJ; Griffiths JR; Rodrigues LM; Stubbs M
    Br J Cancer; 1995 Oct; 72(4):905-11. PubMed ID: 7547238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.
    Li L; Rojiani A; Siemann DW
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):899-903. PubMed ID: 9845118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
    Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
    Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
    Winn BA; Devkota L; Kuch B; MacDonough MT; Strecker TE; Wang Y; Shi Z; Gerberich JL; Mondal D; Ramirez AJ; Hamel E; Chaplin DJ; Davis P; Mason RP; Trawick ML; Pinney KG
    J Nat Prod; 2020 Apr; 83(4):937-954. PubMed ID: 32196334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic contrast-enhanced MRI in mouse tumors at 11.7 T: comparison of three contrast agents with different molecular weights to assess the early effects of combretastatin A4.
    Fruytier AC; Magat J; Neveu MA; Karroum O; Bouzin C; Feron O; Jordan B; Cron GO; Gallez B
    NMR Biomed; 2014 Nov; 27(11):1403-12. PubMed ID: 25323069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs.
    Pettit GR; Lippert JW
    Anticancer Drug Des; 2000 Jun; 15(3):203-16. PubMed ID: 11049088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphorus-31 magnetic resonance spectroscopy and blood perfusion of the RIF-1 tumor following X-irradiation.
    Tozer GM; Bhujwalla ZM; Griffiths JR; Maxwell RJ
    Int J Radiat Oncol Biol Phys; 1989 Jan; 16(1):155-64. PubMed ID: 2912937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.
    Tozer GM; Prise VE; Wilson J; Locke RJ; Vojnovic B; Stratford MR; Dennis MF; Chaplin DJ
    Cancer Res; 1999 Apr; 59(7):1626-34. PubMed ID: 10197639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting tumour vasculature: the development of combretastatin A4.
    Griggs J; Metcalfe JC; Hesketh R
    Lancet Oncol; 2001 Feb; 2(2):82-7. PubMed ID: 11905799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of murine radiation-induced fibrosarcoma-1 tumor metabolism and blood flow in situ via glucose and mannitol administration monitored by 31P and 2H nuclear magnetic resonance spectroscopy.
    Hwang YC; Kim SG; Evelhoch JL; Seyedsadr M; Ackerman JJ
    Cancer Res; 1991 Jun; 51(12):3108-18. PubMed ID: 1904001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
    Galbraith SM; Chaplin DJ; Lee F; Stratford MR; Locke RJ; Vojnovic B; Tozer GM
    Anticancer Res; 2001; 21(1A):93-102. PubMed ID: 11299795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging.
    Thoeny HC; De Keyzer F; Vandecaveye V; Chen F; Sun X; Bosmans H; Hermans R; Verbeken EK; Boesch C; Marchal G; Landuyt W; Ni Y
    Radiology; 2005 Nov; 237(2):492-9. PubMed ID: 16192323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI.
    Maxwell RJ; Wilson J; Prise VE; Vojnovic B; Rustin GJ; Lodge MA; Tozer GM
    NMR Biomed; 2002 Apr; 15(2):89-98. PubMed ID: 11870904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 31P-nuclear magnetic resonance spectroscopy in vivo of six human melanoma xenograft lines: tumour bioenergetic status and blood supply.
    Lyng H; Olsen DR; Southon TE; Rofstad EK
    Br J Cancer; 1993 Dec; 68(6):1061-70. PubMed ID: 8260356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue.
    Griggs J; Hesketh R; Smith GA; Brindle KM; Metcalfe JC; Thomas GA; Williams ED
    Br J Cancer; 2001 Mar; 84(6):832-5. PubMed ID: 11259100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.